EnglishJapaness Traditional Chinese Simplified Chinese
Ȩ > ±Û·Î¹úÆÄÆ®³Ê > Mellalta Meets LLP

Mellalta Meets LLP

Melalta Meets´Â ¿¬±¸ ±â¹ÝÀÇ ±Û·Î¹ú ½ÃÀå Á¶»ç ¹× ÄÁ¼³ÆÃ ±â¾÷À¸·Î, Àü ¼¼°èÀÇ ´Ù¾çÇÑ ±â¾÷¿¡°Ô ÃÖÀûÈ­µÈ »ç¾÷ Àü·«À» Á¦°øÇÏ¿© ´õ ³ªÀº »ç¾÷ °áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ƯÈ÷ Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ÀÌ °æÀï·ÂÀ» À¯ÁöÇÒ ¼ö ÀÖµµ·Ï ¸ÂÃãÇü ½ÃÀå º¸°í¼­¸¦ Á¦°øÇÕ´Ï´Ù.
°Ë»ö
Á¦¸ñ°Ë»ö
1 - 25 ¸®ºä (Àüü£º 38 °Ç) Á¤·Ä Ç¥½Ã °Ç¼ö
Benign Prostatic Hyperplasia (BPH) - Current Landscape & Epidemiology Forecast 2033
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1223535
¹ßÇàÀÏ
2023³â 01¿ù
ÆäÀÌÁö Á¤º¸
110 Pages
°¡°Ý
US $ 3,800 -> £Ü 4,933,000
Neuromyelitis Optica Spectrum Disorder (NMOSD) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1170393
¹ßÇàÀÏ
2022³â 12¿ù
ÆäÀÌÁö Á¤º¸
196 Pages
°¡°Ý
US $ 6,500 -> £Ü 8,439,000
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1170398
¹ßÇàÀÏ
2022³â 12¿ù
ÆäÀÌÁö Á¤º¸
87 Pages
°¡°Ý
US $ 3,500 -> £Ü 4,544,000
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1170397
¹ßÇàÀÏ
2022³â 12¿ù
ÆäÀÌÁö Á¤º¸
95 Pages
°¡°Ý
US $ 3,500 -> £Ü 4,544,000
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1170396
¹ßÇàÀÏ
2022³â 12¿ù
ÆäÀÌÁö Á¤º¸
188 Pages
°¡°Ý
US $ 3,500 -> £Ü 4,544,000
Severe Influenza| Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1170395
¹ßÇàÀÏ
2022³â 11¿ù
ÆäÀÌÁö Á¤º¸
181 Pages
°¡°Ý
US $ 6,500 -> £Ü 8,439,000
Narcolepsy| Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1170394
¹ßÇàÀÏ
2022³â 09¿ù
ÆäÀÌÁö Á¤º¸
217 Pages
°¡°Ý
US $ 6,500 -> £Ü 8,439,000
ER+/HER2- Metastatic Breast Cancer (mBC)| Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1114725
¹ßÇàÀÏ
2022³â 08¿ù
ÆäÀÌÁö Á¤º¸
356 Pages
°¡°Ý
US $ 6,500 -> £Ü 8,439,000
Metastatic Ovarian Cancer (mOC)| Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1114726
¹ßÇàÀÏ
2022³â 08¿ù
ÆäÀÌÁö Á¤º¸
388 Pages
°¡°Ý
US $ 6,500 -> £Ü 8,439,000
Prader-Willi Syndrome (PWS)| Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1114727
¹ßÇàÀÏ
2022³â 07¿ù
ÆäÀÌÁö Á¤º¸
166 Pages
°¡°Ý
US $ 6,500 -> £Ü 8,439,000
Dravet Syndrome (DS) | Primary Research (KOL's Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1089231
¹ßÇàÀÏ
2022³â 05¿ù
ÆäÀÌÁö Á¤º¸
141 Pages
°¡°Ý
US $ 6,000 -> £Ü 7,790,000
Major Depressive Disorder (MDD) | Primary Research (KOL's Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1067325
¹ßÇàÀÏ
2022³â 03¿ù
ÆäÀÌÁö Á¤º¸
267 Pages
°¡°Ý
US $ 6,500 -> £Ü 8,439,000
Rett Syndrome (RTT) | Primary Research (KOL's Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1067324
¹ßÇàÀÏ
2022³â 02¿ù
ÆäÀÌÁö Á¤º¸
165 Pages
°¡°Ý
US $ 6,500 -> £Ü 8,439,000
Anti-Cluster of differentiation 38 (CD38) Antibody - Pipeline Analytics 2022
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1067322
¹ßÇàÀÏ
2022³â 01¿ù
ÆäÀÌÁö Á¤º¸
86 Pages
°¡°Ý
US $ 2,500 -> £Ü 3,246,000
Anti-Cluster of differentiation 19 (CD19) Antibody - Pipeline Analytics 2022
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1067323
¹ßÇàÀÏ
2022³â 01¿ù
ÆäÀÌÁö Á¤º¸
71 Pages
°¡°Ý
US $ 2,500 -> £Ü 3,246,000
Pediatric Crohn's Disease (pCD)| Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast - 2030
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1043374
¹ßÇàÀÏ
2021³â 11¿ù
ÆäÀÌÁö Á¤º¸
182 Pages
°¡°Ý
US $ 6,500 -> £Ü 8,439,000
Metastatic Renal Cell Carcinoma (mRCC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast - 2030
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1043373
¹ßÇàÀÏ
2021³â 11¿ù
ÆäÀÌÁö Á¤º¸
293 Pages
°¡°Ý
US $ 6,500 -> £Ü 8,439,000
Gamma Delta T Cell Therapy - Pipeline Analytics 2021
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1043370
¹ßÇàÀÏ
2021³â 10¿ù
ÆäÀÌÁö Á¤º¸
125 Pages
°¡°Ý
US $ 2,500 -> £Ü 3,246,000
Cluster of Differentiation 47 (CD47) Inhibitors - Pipeline Analytics 2021
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1043371
¹ßÇàÀÏ
2021³â 10¿ù
ÆäÀÌÁö Á¤º¸
151 Pages
°¡°Ý
US $ 2,500 -> £Ü 3,246,000
Anti Neutralizing Antibodies (NAbs) Gene Therapies - Pipeline Analytics 2021
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1043369
¹ßÇàÀÏ
2021³â 10¿ù
ÆäÀÌÁö Á¤º¸
110 Pages
°¡°Ý
US $ 2,500 -> £Ü 3,246,000
Complex Regional Pain Syndrome (CRPS)| Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast - 2030
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1031004
¹ßÇàÀÏ
2021³â 10¿ù
ÆäÀÌÁö Á¤º¸
147 Pages
°¡°Ý
US $ 6,500 -> £Ü 8,439,000
Lumbar Radiculopathy (Sciatica)| Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast - 2030
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1031005
¹ßÇàÀÏ
2021³â 10¿ù
ÆäÀÌÁö Á¤º¸
181 Pages
°¡°Ý
US $ 6,500 -> £Ü 8,439,000
Signaling Regulatory Protein (SIRP) alpha Inhibitors - Pipeline Analytics 2021
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1043368
¹ßÇàÀÏ
2021³â 09¿ù
ÆäÀÌÁö Á¤º¸
101 Pages
°¡°Ý
US $ 2,500 -> £Ü 3,246,000
Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors - Pipeline Analytics 2021
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1043367
¹ßÇàÀÏ
2021³â 09¿ù
ÆäÀÌÁö Á¤º¸
140 Pages
°¡°Ý
US $ 2,500 -> £Ü 3,246,000
Mitochondrial Epilepsy (MIT-E) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast - 2030
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óǰÄÚµå
1030730
¹ßÇàÀÏ
2021³â 08¿ù
ÆäÀÌÁö Á¤º¸
151 Pages
°¡°Ý
US $ 6,500 -> £Ü 8,439,000

»ó±â ÀÚ·á ÀÌ¿ÜÀÇ Mellalta Meets LLP ÀÚ·áµµ ÁÖ¹® °¡´ÉÇÏ´Ï ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦